scholarly journals Long-term use of topical tacrolimus ointment: a safe and effective option for the treatment of vernal keratoconjunctivitis

2019 ◽  
Vol 82 (2) ◽  
Author(s):  
Guilherme Gubert Müller ◽  
Newton Kara José ◽  
Rosane Silvestre de Castro ◽  
Erick Carneiro de Holanda
Keyword(s):  
Vernal Keratoconjunctivitis ◽  
Tacrolimus Ointment ◽  
Topical Tacrolimus ◽  
Effective Option

scholarly journals The Efficacy of 0.03% Dermatological Tacrolimus Ointment for Refractory Vernal Keratoconjunctivitis.

2020 ◽  
Vol 35 (4) ◽  
pp. 229-234
Author(s):  
Hafiza Sadia Imtiaz
Keyword(s):  
Clinical Symptoms ◽  
Clinical Signs ◽  
Vernal Keratoconjunctivitis ◽  
P Value ◽  
Baseline Score ◽  
Assessment Data ◽  
Tacrolimus Ointment ◽  
Topical Tacrolimus ◽  
Quasi Experimental ◽  
Written Informed Consent

  Purpose: To determine the efficacy of 0.03% dermatological tacrolimus ointment in patients with refractory vernal keratoconjunctivitis Study Design: Quasi-experimental study Study Place and Duration: Eye Department, DHQ-Teaching Hospital, Gujranwala, Pakistan from April 2018 to March 2019 Material and Methods: After approval from hospital ethical committee and obtaining written informed consent from each patient/guardian, patients of either gender between 4-16 years of age with VKC not responding to conventional treatment for more than 8 weeks or having steroid-induced complications were included in this study. Dermatological tacrolimus ointment 0.03% started to be placed in inferior fornix in BD frequency along with topical lubricants. Patients were followed up on a regular schedule. Individual symptoms score was assessed from the questionnaire and signs score from observer’s clinical assessment. Data were analyzed using SPSS v23.0. P-value <0.05 was considered as statistically significant. Results: 40 eyes of 20 patients were included in this study. Out of which 4(20%) were female and 16 were male (80%). Mean baseline score for clinical symptoms was 6.65±1.81 that reduced to 1.65±0.81 after 12 weeks treatment course of tacrolimus with a significant p-value of 0.006 (p<0.05). Mean baseline score for clinical signs was 5.9±1.59 that improved to 1.80±0.83 after 12 weeks treatment course with a statistically significant p-value of 0.003 (p<0.05). Conclusions: In conclusion, topical tacrolimus dermatological ointment 0.03% is highly effective in refractory VKC and can be safely used as an alternative in VKC patients who are steroid-responders.

scholarly journals Long-term results of topical 0.02% tacrolimus ointment for refractory ocular surface inflammation in pediatric patients

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Kyungmin Koh ◽  
Ikhyun Jun ◽  
Tae-im Kim ◽  
Eung Kweon Kim ◽  
Kyoung Yul Seo
Keyword(s):  
Ocular Surface ◽  
Pediatric Patients ◽  
Clinical Signs ◽  
Long Term Results ◽  
Tacrolimus Ointment ◽  
Topical Tacrolimus ◽  
Surface Inflammation ◽  
Ocular Surface Inflammation

Abstract Background No studies have been reported on the efficacy and safety of long-term (≥12 months) use of topical tacrolimus for refractory ocular surface inflammation in pediatric patients. Methods Medical records of pediatric patients who were prescribed topical 0.02% tacrolimus ointment for refractory ocular surface inflammation between January of 2010 and March of 2018 were reviewed retrospectively. Changes in ocular surface signs during slit-lamp examination, clinical symptoms and concurrent steroid use were graded with a scoring system. The presence of side effects was also assessed. The changes in disease severity and patient symptoms were compared between baseline and after the treatment. Results Among 72 patients (55% males, mean age 10.8 ± 3.9 years, range 3 to 17 years), 25 patients (48% males, mean age 11.4 ± 3.9 years) fully recovered, resulting in discontinuance of the ointment treatment before 12 months. Six patients experienced intolerable burning sensation, which required treatment cessation. Cessation days of those who quit were 1,5,14,20,26, and 35 days. Seven patients were lost during follow-up. Thirty-four patients (56% males, mean age 11.2 ± 4.2 years, range 3 to 17 years) were treated with tacrolimus ointment for over 12 months (average 23.1 ± 19.1 months, range 12 to 98 months). During the follow-up period, all patients showed improved clinical signs and symptoms, and no adverse reaction was noted. Conclusions Long-term maintenance of topical tacrolimus 0.02% ointment is safe and effective in improving refractory ocular surface inflammation in pediatric patients.

scholarly journals Long-term Results of Topical 0.02% Tacrolimus Ointment for Refractory Ocular Surface Inflammation in Pediatric Patients

2021 ◽  
Author(s):  
Kyungmin Koh ◽  
Ikhyun Jun ◽  
Tae-im Kim ◽  
Eung Kweon Kim ◽  
Kyoung Yul Seo
Keyword(s):  
Ocular Surface ◽  
Pediatric Patients ◽  
Anterior Segment ◽  
Long Term Results ◽  
Slit Lamp ◽  
Tacrolimus Ointment ◽  
Topical Tacrolimus ◽  
Long Term Treatment

Abstract Background: To investigate the efficacy and safety of long-term treatment with topical 0.02 % tacrolimus ointment for ocular inflammation in pediatric patients. No studies have been reported on the outcome of long-term (≥12 months) use of topical tacrolimus in pediatric patients for treatment of ocular surface diseases. Methods: A total of 144 eyes of 72 pediatric patients who were prescribed topical 0.02% tacrolimus ointment between January of 2010 and March of 2018 for anterior segment inflammatory disorders refractory to conventional steroid therapy were included. Patients completed questionnaires and underwent slit-lamp examinations for evaluation of symptoms and signs at baseline. Patients were followed 1, 2, 3, 6, 9 and 12 months after initiation of tacrolimus treatment. After 12 months, patients were followed every 3 months for monitoring of possible adverse events and clinical outcomes. Changes in ocular surface parameters during slit-lamp examination, clinical symptoms and concurrent steroid use were graded with a scoring system. The presence of side effects was also verified.Results: Among 72 patients (56 % males, age 10.79 ± 3.96 years), 25 patients (48% males, age 11.42 ± 3.91 years) fully recovered, resulting in discontinuance of the ointment treatment before 12 months. Six patients experienced intolerable burning sensation, which required treatment cessation. Cessation days of those who quit were 1,5,14,20,26, and 35 days. Seven patients were lost during follow-up. Thirty-four patients (56% males, age 11.20 ± 4.21 years) were treated with tacrolimus ointment for over 12 months (average 23.12 ± 19.07 months). During the follow-up period, all patients showed improved clinical signs and symptoms, and no adverse reaction was noted. Conclusions: Long-term maintenance of topical tacrolimus 0.02% ointment is safe and effective in improving refractory ocular surface inflammatory diseases in pediatric patients.

scholarly journals SURG-02. INITIAL MANAGEMENT OF HYDROCEPHALUS IN THE PEDIATRIC AND YOUNG-ADULT PATIENTS WITH BRAIN TUMORS; THE EFFICACY OF LONG-TERM INDWELLING EXTERNAL VENTRICULAR DRAINAGE

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii461-iii461
Author(s):  
Shigeru Yamaguchi ◽  
Hiroaki Motegi ◽  
Yukitomo Ishi ◽  
Michinari Okamoto ◽  
Akihiro Iguchi ◽  
...  
Keyword(s):  
Brain Tumor ◽  
Young Adult ◽  
Brain Tumors ◽  
External Ventricular Drainage ◽  
The Body ◽  
Ventricular Drainage ◽  
Initial Management ◽  
Effective Option ◽  
Csf Diversion

Abstract BACKGROUND Pediatric and Young-Adult (AYA) brain tumors often present with hydrocephalus. As temporary cerebrospinal fluid (CSF) diversion procedure, we perform long-term indwelling external ventricular drainage (EVD) in the case of the management of CSF diversion more than two weeks presumably. The aim of this study is to investigate the initial management for hydrocephalus in pediatric /AYA patients with brain tumor, especially about long-term EVD. MATERIALS AND METHODS The patients less than 30 years of age diagnosed with brain tumor between 2005 and 2019 were retrospectively analyzed. Procedures of long-term EVD were similar to that of ventriculoperitoneal shunt (VPS) operation. Using flow-control VPS system, peritoneal catheter passed out of the body at the anterior chest, and distal end of the catheter was connected to standard EVD system. RESULTS In total of 345 patients with brain tumor, 109 had hydrocephalus at presentation. Among them, 25 patients (23%) underwent long-term EVD. The main reasons for selecting long-term EVD were to avoid intraperitoneal dissemination (n=13), and to maintain longer period of CSF diversion for the treatment of tumor (n=12). The median of long-term EVD was 38 days (range: 12 – 222 days). Although one case suffered from drainage tube occlusion at 59 days, there were no other complications such as infection or accidental evulsion. Eventually, 3 cases required permanent VPS for persistent hydrocephalus. CONCLUSION Long-term EVD is safe and effective option for CSF diversion. This procedure should be taken into consideration if patients have a risk of dissemination and may elude permanent VPS.

Long-Term Safety and Efficacy of Tacrolimus 0.1% in Severe Pediatric Vernal Keratoconjunctivitis

Cornea ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Roberto Caputo ◽  
Elisa Marziali ◽  
Cinzia de Libero ◽  
Laura Di Grande ◽  
Gioia Danti ◽  
...  
Keyword(s):  
Vernal Keratoconjunctivitis ◽  
Safety And Efficacy

Topical tacrolimus ointment for the treatment of lichen sclerosus, comparing genital and extragenital involvement

2011 ◽  
Vol 39 (2) ◽  
pp. 145-150 ◽  
Author(s):  
Gun-Wook KIM ◽  
Hyun-Je PARK ◽  
Hoon-Soo KIM ◽  
Su-Han KIM ◽  
Hyun-Chang KO ◽  
...  
Keyword(s):  
Lichen Sclerosus ◽  
Tacrolimus Ointment ◽  
Topical Tacrolimus

Topical tacrolimus 0.03% monotherapy for vernal keratoconjunctivitis--case series

2010 ◽  
Vol 94 (10) ◽  
pp. 1405-1406 ◽  
Author(s):  
P. M. K. Tam ◽  
A. L. Young ◽  
L. L. Cheng ◽  
P. T. H. Lam
Keyword(s):  
Case Series ◽  
Vernal Keratoconjunctivitis ◽  
Topical Tacrolimus

scholarly journals Efficacy of Narrow-Band Ultra Violet B versus Narrow-Band Ultra Violet B with Topical Tacrolimus Ointment (0.1%) in the Treatment of Vitiligo

2017 ◽  
Vol 13 (1) ◽  
pp. 86-89
Author(s):  
Jweena Bintey Jamal ◽  
Muhammed Ashraful Alam Bhuiyan ◽  
Md Abdul Latif Khan
Keyword(s):  
Narrow Band ◽  
Excellent Result ◽  
Ultra Violet ◽  
Armed Forces ◽  
Military Hospital ◽  
Tacrolimus Ointment ◽  
Topical Tacrolimus ◽  
Group A ◽  
Group B ◽  
Response Score

Introduction: Several treatment options e.g. topical corticosteroids, phototherapy like narrow-band ultra violet B (NB-UVB) and psoralen+ultra violet A (PUVA) etc are available for vitiligo. But none is so effective in single but combined one is more effective and superior. Objective: To compare the efficacy of NB-UVB vs NB-UVB with topical Tacrolimus ointment (0.1%) in the treatment of Vitiligo. Materials and Methods: This descriptive cross-sectional study was conducted in Combined Military Hospital, Dhaka from October 2015 to April 2016. Total 100 patients with vitiligo were divided into 2 groups of 50 patients. NB-UVB was given for 04 weeks to Group-A. In Group-B patients, topical Tacrolimus ointment (0.1%) twice daily was advised with simultaneous NB-UVB. The patients were followed-up at the baseline of the 4th, 8th and 16th week. Results: Majority (46%) of the patients were from 25-34 years of age with a mean age of 27.4±12.6 years. Among all risk factors, Family history of Vitiligo was the most common risk factor and common skin type (Fitzpatrick) was Type IV (40%). At the end of 4th week, maximum cases of Group-B showed good response (score 3) with a mean score of 1.74. Whereas, maximum cases of Group-A showed poor response (score 1) with a mean score of 0.86. End of the 16th week, maximum cases of Group-B improved successfully. In the end, 20% patients of Group-A showed an excellent result; but it was 42% from Group-B. Conclusion: It is revealed from this study that patients treated with a combination of NB-UVB with topical Tacrolimus ointment (0.1%) showed better treatment outcome, more effective and becomes a new mode of treatment. Journal of Armed Forces Medical College Bangladesh Vol.13(1) 2017: 86-89

Sign in / Sign up

Export Citation Format

Share Document